Why Coherus Oncology, Inc.’s (CHRS) Stock Is Down 6.03%
As of Monday, August 31, Coherus Oncology, Inc.’s CHRS share price has dipped by 6.03%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Commentary & Analysis
Why Coherus Oncology, Inc.’s (CHRS) Stock Is Up 6.44%
As of Friday, August 21, Coherus Oncology, Inc.’s CHRS share price has surged by 6.44%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Coherus Oncology, Inc.’s (CHRS) Stock Is Up 7.39%
As of Tuesday, August 18, Coherus Oncology, Inc.’s CHRS share price has surged by 7.39%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Coherus Oncology, Inc.’s (CHRS) Stock Is Up 14.35%
As of Tuesday, August 18, Coherus Oncology, Inc.’s CHRS share price has surged by 14.35%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Coherus Oncology, Inc.’s (CHRS) Stock Is Up 8.70%
As of Friday, August 07, Coherus Oncology, Inc.’s CHRS share price has surged by 8.70%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | CHRS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $219.4 | $288.9 | 28% |
|
| Shares Out (Mil) | 154.8 | 54.0 | 71% |
|
| Institutional Ownership | 77.8% | 93.1% | 47% |
|
| Float (Mil) | 135.6 | 41.4 | 67% |
|
| Beta | 0.95 | 0.94 | 57% |
|
| Avg Daily Volume (000s) | 939 | 480 | 71% |
|
| Price Change (52-week) |
19.3% | 59.9% | 63% |
|
| Growth | CHRS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (38.4%) | 14.1% | 1% |
|
| Net Income (5yr) | 4.9% | (10.1%) | 47% |
|
| EPS (5yr) | (2.5%) | 15.9% | 28 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.6%) | (15.6%) | 48% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.210) | ($0.855) | ($0.630) | |
| Month Ago EPS | ($0.225) | ($0.745) | ($1.020) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.225) | ($0.745) | ($1.020) | |
| Year/Year Chg | (2.3%) | (45.3%) | (53.6%) | |
| Financials | CHRS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $51 | $37 | 20% |
|
| Net Income (TTM) (Mil) | ($132) | ($43) | 9% |
|
| EPS (TTM) | ($1.001) | ($1.500) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($186) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($134) | $2 | 12% |
|
| Long-Term Debt (Q1) (Mil) | $52 | $4 | 39% |
|
| Enterprise Value (Q1) (Mil) | $145 | $190 | 24% |
|
| Valuation | CHRS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.64 | 2.84 | 70% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CHRS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 69.0% | 66.9% | 80% |
|
| Net Margin | (259.4%) | (74.2%) | 4% |
|
| ROA | (41.9%) | (47.7%) | 13% |
|
| ROE | (146.3%) | (55.0%) | 6% |
|
| Liabilities to Assets | 68.2% | 29.6% | 64% |
|
| F-Score | 3 | 3 | 18% |
|
Coherus Oncology, Inc. did not pass any screens on 9/2/2026.
